SLXN
NASDAQ · Biotechnology
Silexion Therapeutics Corp
$2.66
-0.57 (-17.65%)
SLXN News2 articles
Silexion Rockets 97% on Cancer Trial News, Nasdaq Compliance and Cash Concerns Remain
Silexion Therapeutics shares surged 97% on Wednesday following Israeli approval for a Phase 2/3 trial of its pancreatic cancer drug SIL204, but the company still grapples with cash burn, dilution risks, and Nasdaq compliance.
Silexion Advances Pancreatic Cancer Trial Amid Cash Concerns
Silexion Therapeutics progresses its SIL204 pancreatic cancer drug into clinical trials, but a shrinking cash position and recent stock decline highlight funding challenges.